Obesity is a risk factor for estrogen receptor-positive (ER+) breast cancer after menopause.
The pro-proliferative effects of estrogens are well characterized and there is a growing body …

How can we treat cancer more effectively? Traditionally, tumours from the same anatomical
site are treated as one tumour entity. This concept has been challenged by recent …

The mechanisms contributing to transcription-associated genomic instability are both
complex and incompletely understood. Although R-loops are normal transcriptional …

Obesity, defined as a body mass index (BMI)≥ 30, is an established risk factor for breast
cancer among women in the general population after menopause. Whether elevated BMI is …

BRCA1 is a major breast and ovarian cancer susceptibility gene, with mutations in this gene
predisposing women to a very high risk of developing breast and ovarian tumours. BRCA1 …

Ovarian cancer is a heterogeneous disease that encompasses a number of different cellular
subtypes, the most common of which is high-grade serous ovarian cancer (HGSOC). Still …

In mammals, secretin is a 27-amino acid peptide that was first studied in 1902 by Bayliss
and Starling from the extracts of the jejunal mucosa for its ability to stimulate pancreatic …

BRCA1—a breast and ovarian cancer suppressor gene—promotes genome integrity. To
study the functionality of BRCA1 in the heterozygous state, we established a collection of …

Cancer development is a complex process driven by inherited and acquired molecular and
cellular alterations. Prevention is the holy grail of cancer elimination, but making this a reality …

Mutations in breast cancer type 1 susceptibility protein (BRCA1) and its heterodimeric
binding partner BARD1 confer a high risk for the development of breast and ovarian …